RxDoctor Payments Data

Jocelyn Hu, MD

Family Medicine · Greenville, TXNPI 1841601283

Payments from drug & device makers

$900in general payments, 2019–2025

Across 49 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$156
  • Abbott$115
  • Amgen$89
  • Novo Nordisk$79
  • Lilly USA, LLC$69
  • Biohaven Pharmaceutical Holding Company Ltd.$69
  • plus $322 from 9 others

What the payments were for

  • Food & beverage$900100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$900 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$20,986
Medicare patients
721
Services billed
1,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$99,697
OzempicSemaglutide56$87,373
TrulicityDulaglutide20$40,466
JardianceEmpagliflozin31$38,977
MounjaroTirzepatide22$35,674
FarxigaDapagliflozin Propanediol28$35,598
Tresiba Flextouch U-200Insulin Degludec14$25,232
XareltoRivaroxaban17$22,657
JanumetSitagliptin Phos/Metformin Hcl23$20,255
JanuviaSitagliptin Phosphate12$17,927
Breo ElliptaFluticasone/Vilanterol23$10,533
MyrbetriqMirabegron15$10,098
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,755
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,022
DapagliflozinDapagliflozin Propanediol12$6,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$99,69796 claims
Novo NordiskOzempic$79$87,37356 claims
Lilly USA, LLCTrulicity, Mounjaro$69$76,14042 claims
MerckJanumet, Januvia$16$38,18135 claims
Johnson & JohnsonXarelto$13$22,65717 claims
GSKBreo Ellipta, Trelegy Ellipta$67$17,55534 claims
Astellas Pharma US IncMyrbetriq$59$10,09815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Greenville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →